Drug Profile
Immune therapeutic protein - Cantech Holdings
Alternative Names: ITPLatest Information Update: 13 Jan 2022
Price :
$50
*
At a glance
- Originator Canteck Pharma
- Developer Cantech Holding
- Class Antineoplastics; Immunotherapies; Proteins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Cancer